Differential inhibition of nucleoside transport systems in mammalian cells by a new series of compounds related to lidoflazine and mioflazine.
The sensitivity of facilitated-diffusion and Na(+)-dependent nucleoside transporters to inhibition by a series of novel compounds related to lidoflazine and mioflazine was investigated. Uridine transport by rabbit erythrocytes, which proceeds solely by the nitrobenzylthioinosine (NBMPR)-sensitive facilitated-diffusion system, was inhibited with apparent Ki values of less than 10 nM by lidoflazine, mioflazine, soluflazine and R73-335. These compounds also blocked site-specific [3H]NBMPR binding to rabbit erthrocyte membranes in a competitive fashion. The NBMPR-sensitive system in rat erythrocytes was also inhibited by lidoflazine, mioflazine, soluflazine and R73-335 but was two to three orders of magnitude less sensitive to inhibition than the system in rabbit erythrocytes (apparent Ki 7.3, 2.4, 5.7 and 0.1 microM, respectively). Lidoflazine, mioflazine and R73-335 exhibited a similar potency for the NBMPR-sensitive and -insensitive nucleoside transporters in rat erythrocytes. In contrast, soluflazine was 20- to 100-fold more potent as an inhibitor of the NBMPR-insensitive nucleoside transport component in rat erythrocytes (IC50 of 0.08-0.2 microM) compared to the NBMPR-sensitive nucleoside carrier in these cells (IC50 approximately 10 microM). None of the test compounds were potent inhibits of Na(+)-dependent uridine transport in bovine renal brush-border membrane vesicles. These results indicate that lidoflazine, mioflazine, soluflazine and R73-335 are selective inhibitors of nucleoside transport in animal cells and that the potency of these compounds as nucleoside transport inhibitors is species dependent.
Griffith
D A
DA
Biological Laboratory, University of Kent, Canterbury, U.K.
Conant
A R
AR
Jarvis
S M
SM
D000345:Affinity Labels; D000818:Animals; D001692:Biological Transport / Q000187:drug effects*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002417:Cattle; D002478:Cells, Cultured / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008013:Lidoflazine / Q000494:pharmacology*; D009705:Nucleosides / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D010920:Placenta / Q000187:drug effects / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D012964:Sodium / Q000494:pharmacology; D013868:Thioinosine / Q000031:analogs & derivatives / Q000378:metabolism; D014529:Uridine / Q000378:metabolism
D000345:Affinity Labels; D002317:Cardiovascular Agents; D009705:Nucleosides; D010879:Piperazines; D013868:Thioinosine; C041518:mioflazine; D012964:Sodium; C001789:4-nitrobenzylthioinosine; D008013:Lidoflazine; D014529:Uridine